TSA Pre-Signing Review
Quantify the regulatory exposure before signing.
Fixed-fee proposal in 48 hours. Senior team on day one. The first conversation is always free.
A medical devices carve-out TSA carries regulated workflows that consumer or industrial deals do not. FDA Quality System Regulation, EU MDR, validated manufacturing systems, complaint handling, post market surveillance, and unique device identification all sit inside the service catalog. The work runs inside the broader carve-out advisory framework with device specific overlays that change the timeline, the controls, and the exit ramp. The buyer that ignores the regulatory layer in pre-signing finds the cost of a missed obligation later in the form of a Form 483 or a Notified Body finding.
The Quality System Regulation under 21 CFR 820 is the spine of every medical device carve-out. The seller's quality management system documents the procedures, work instructions, design history files, device master records, and management responsibilities for every device the Newco will own. The Newco needs continuity of those records from the moment the registration transfers. A Newco that operates without a complete quality management system from Day One is a Newco one inspection away from a consent decree.
The carve-out has to address each procedure individually. A procedure that applies only to Newco devices can be exported, retitled under the Newco quality management system, and signed off by the Newco's management representative. A procedure shared across the seller's other devices has to be cloned and adapted. The discipline is to inventory every controlled document, identify the disposition, and execute the transfer with formal change control evidence on both sides.
A pre-signing assessment of the seller's quality management system, the documents in scope, the document control system, and the management of change protocols is the first deliverable. Without it the Day One quality posture is a guess. The pattern overlaps with the broader carve-out Day One readiness playbook.
Validated systems including the electronic quality management system, the manufacturing execution system, the laboratory information management system, the document management system, and the enterprise resource planning system all carry validation packages under FDA 21 CFR Part 11. The Newco cannot just lift and shift these systems. Each system requires either a continued validated state in the destination tenant, or a fresh validation effort if the move involves a new instance.
The TSA usually keeps the seller hosting validated systems for an extended period. The cost of revalidation is the dominant driver of TSA duration in medical device deals. A buyer who insists on a fast exit may incur revalidation costs that exceed the extension fee for several quarters of TSA service. The economic decision needs to be made with the validation lead, the regulatory affairs team, and the CFO in the room.
When the validated system migrates, the package travels with it. Installation qualification, operational qualification, and performance qualification all require fresh evidence on the destination. Audit trail continuity has to be preserved. The pattern overlaps with the broader TSA exit data migration strategy playbook.
Complaint handling under 21 CFR 820.198 and Medical Device Reporting under 21 CFR 803 do not pause for the carve-out. A complaint received on Day One has to be triaged, investigated, and where required reported to the FDA within thirty days. The Newco needs an operational complaint handling process from sunrise on Day One. Most carve-outs run the complaint flow through the seller for an initial period, with Newco staff embedded, before the function transfers fully.
Open Corrective and Preventive Action records transfer with the device. Each open CAPA has an investigation trail, a root cause analysis, an action plan, and effectiveness checks. The seller hands over the open record. The Newco accepts continued ownership and reports progress under the Newco's quality management system. A CAPA that loses momentum during the carve-out becomes the first finding in the next inspection.
Post market surveillance under EU MDR Article 83 is the third discipline. Periodic Safety Update Reports for class IIa, class IIb, and class III devices follow a fixed cadence that does not pause for ownership change. The Newco's regulatory team has to take responsibility for the relevant cycles from Day One and document the transition in the post market surveillance plan.
Every device the Newco will own is registered with one or more regulatory authorities. The FDA establishment registration, the device listing, the EU UDI database entry, the Health Canada Medical Device Licence, and the registrations across other markets all have to be updated to reflect the Newco. The transfer process differs by jurisdiction. Some require a simple notification. Others require a full re registration. The lead time spans weeks to months and the work has to start during pre-signing.
Notified Body certificates under EU MDR transfer through a defined process. The Notified Body has to consent to the transfer, conduct a transfer audit, and reissue the certificates under the Newco's name. The timing window has to be planned. A Newco that ships product in the EU without valid certificates faces import seizure and a class action waiting to happen.
Unique Device Identification labelling continues unchanged for product already in distribution. New production may carry the Newco's labeller identifier. The cutover plan should specify when the labeller identifier changes and how distributors are informed. The pattern overlaps with the broader Day One regulatory filings playbook.
Distributor agreements, contract manufacturer agreements, sterilisation supplier agreements, and component supplier agreements all need a formal assignment to the Newco. Some assign with consent only. Some require a full requalification of the supplier under the Newco's supplier quality management system. A supplier qualification record that lives in the seller's system has to either travel to the Newco or be recreated through a fresh qualification visit.
Traceability is the second discipline. Lot, serial, and batch traceability runs from raw material through manufacturing through distribution to the end user. A Newco needs unbroken traceability from Day One because a recall on Day Two has no margin for confusion about who shipped what to whom. The carve-out plan has to confirm the traceability data sits in systems the Newco controls or accesses under the TSA.
Distributor communication is the third discipline. Distributors need to know the new legal entity, the new ordering process, the new complaint contact, the new vigilance contact, and the timing of any system changes. The communication runs through the carve-out customer communication plan and pairs with the broader carve-out vendor contract assignments playbook.
A clean medical device TSA exit closes three records. The Newco operates a complete quality management system under its own management representative. Every validated system runs in the Newco's environment with its own validation evidence. Every registration, certificate, and listing reflects the Newco. The cutover documentation supports the broader TSA exit certificate and the audit committee can rely on a single regulatory perimeter.
Open items, typically a small set of in flight CAPAs and post market surveillance cycles started under the seller, are tracked under a short post-close services agreement with a hard end date. The agreement specifies the seller's continued cooperation on legacy investigations and the Newco's takeover of forward responsibility. A Notified Body or FDA inspection during the post-close window deserves a coordinated response on both sides.
Specialist support across the medical device carve-out is part of the TSA Pre-Signing Review service when the buyer wants the regulatory exposure quantified before signing. The work coordinates with the Newco's regulatory affairs lead, the quality lead, the CIO, and the seller's quality and validation teams.
HIPAA boundaries, EHR separation, and the disciplined exit ramp.
Read the article →GxP continuity, clinical data, and regulatory submissions during a carve-out.
Read the article →Plant level cutovers, supplier consents, and the manufacturing TSA exit.
Read the article →The 90-day governance, IT, finance, HR and procurement separation plan we run on live carve-outs. Get the playbook plus the bi-weekly Day One Letter — short, signal-heavy, buyer-side.
No spam. Unsubscribe in one click. · Read the overview first →
Fixed-fee proposal in 48 hours. Senior team on day one. The first conversation is always free.
Seven buyer-side moves to exit a Transition Services Agreement on time and below budget. The mark-up, the extension-fee curve, exit sequencing, and the 11-month calendar.
One tactic, one benchmark, or one pattern from a recent buyer-side engagement. Short. Signal heavy. Free.
Subscribe to The Day One Letter →Set the standalone target operating model before the first cutover. Separation without a destination just rebuilds the seller's stack at the seller's cost.